Recent studies have delineated cancer-type-specific roles of histone 3 lysine 27 (H3K27) demethylase KDM6B/JMJD3 depending on its H3K27 demethylase activity. Here we show that KDM6B is expressed in multiple myeloma (MM) cells; and that shRNA-mediated knockdown and CRISPR-mediated knockout of KDM6B abrogate MM cell growth and survival. Tumor necrosis factor-α or bone marrow stromal cell culture supernatants induce KDM6B, which is blocked by IKKβ inhibitor MLN120B, suggesting that KDM6B is regulated by NF-κB signaling in MM cells. RNA-seq and subsequent ChIP-qPCR analyses reveal that KDM6B is recruited to the loci of genes encoding components of MAPK signaling pathway including ELK1 and FOS, and upregulates expression of these genes without affecting H3K27 methylation level. Overexpression of catalytically inactive KDM6B activates expression of MAPK pathwayrelated genes, confirming its function independent of demethylase activity. We further demonstrate that downstream targets of KDM6B, ELK1 and FOS, confer MM cell growth. Our study therefore delineates KDM6B function that links NF-κB and MAPK signaling pathway mediating MM cell growth and survival, and validates KDM6B as a novel therapeutic target in MM.
INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy that proliferates in the bone marrow. 1, 2 Although novel agents including proteasome inhibitors and immunomodulatory drugs (IMiDs) have remarkably improved MM patient survival, MM remains incurable. Hence, there is a need to decipher the pathogenesis of MM to identify novel therapeutic targets. Recent studies using whole-genome and whole-exome sequencing have identified driver mutations in MM, and revealed relevant pathways in myelomagenesis. 3 For example, MAPK pathway genes, including KRAS, NRAS and BRAF, are mutated in about 40% of patients. [4] [5] [6] NF-κB pathway molecules such as TRAF3, CYLD and LTB are also mutated in about 20% of patients. [4] [5] [6] These results highlight the roles of these two signaling pathways in MM. These pathways are also known to be activated by extrinsic factors in the bone marrow microenvironment. 1, 2 For example, bone marrow stromal cells (BMSCs) produce extrinsic ligands, including interleukin-6, insulinlike growth factor 1 (IGF1), tumor necrosis factor-α (TNF-α), a proliferation inducing ligand (APRIL) and B cell activating factor (BAFF), further activating MAPK and NF-κB pathways. Thus, MM cells are largely dependent on these two major pathways.
Lysine demethylase 6B (KDM6B, also known as JMJD3) is a Jumonji C-domain-containing histone demethylase, which removes histone 3 lysine 27 (H3K27) di-and tri-methylation (me2/me3) through iron and α-ketoglutarate-dependent oxidative reactions. [7] [8] [9] KDM6B is upregulated via NF-κB binding to its promoter region by inflammatory stimuli in macrophages. 7 KDM6B contributes not only to inflammatory response, but also to various biological processes, including stress-induced senescence, development and differentiation. [7] [8] [9] [10] [11] [12] [13] Importantly, recent studies have also shown that KDM6B is implicated in the pathogenesis of several cancers in a context-dependent manner; [14] [15] [16] [17] [18] [19] however, to date the biological function of KDM6B in MM remains to be determined.
Here we investigate the biological impact of KDM6B in MM. We show that KDM6B is highly expressed in MM cells. Depletion of KDM6B leads to MM cell death. KDM6B is activated by NF-κB signaling in MM cells, consistent with previous reports in other cell types. 7, 14 Importantly, we demonstrate that KDM6B, in a demethylase-independent manner, upregulates MAPK signaling molecules mediating MM cell growth and survival. Our data therefore delineate the biologic sequelae of KDM6B, and validate KDM6B as a novel therapeutic target in MM.
MATERIALS AND METHODS

Reagents and antibodies
Reagents used in this study are described in Supplementary Materials and Methods. Antibodies used in this study are listed in Supplementary Table 1 .
Cell lines
Human MM cell lines MM.1S, RPMI 8226, KMM-1, NCI-H929, KMS-11 and KMS-27 were stocked in our laboratory, and the identity of these cell lines was confirmed before use by STR profiling (GenePrint10 System, Promega, Madison, WI, USA). Human MM cell lines MOLP-8 and KMS-20 were recently obtained from DSMZ (Braunschweig, Germany) and JCRB Cell Bank (Osaka, Japan), respectively. Human embryonic kidney cell line 293T was obtained from ATCC (Manassas, VA, USA). Cell lines were regularly tested to rule out mycoplasma contamination.
Primary MM cell, BMSC and peripheral blood mononuclear cell samples
Bone marrow or peripheral blood samples were obtained from MM patients or healthy volunteers with informed consent and approval of the Institutional Review Board of the Dana-Farber Cancer Institute. After separating mononuclear cells from patients' bone marrow by Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK), MM cells were purified by CD138positive selection using anti-CD138 magnetic activated cell separation microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Long-term MM patient BMSCs were established and maintained by culturing CD138negative bone marrow mononuclear cells in DMEM containing 100 U/ml penicillin and 100 μg/ml streptomycin, supplemented with 15% (v/v) fetal bovine serum (FBS). Peripheral blood mononuclear cells were isolated from normal donors' peripheral blood using Ficoll-Paque centrifugation.
RNA-seq analysis
Detailed method is found in Supplementary Materials and Methods. RNAseq data are deposited at https://www.ncbi.nlm.nih.gov/geo/ under accession number GSE93395.
Statistical analysis
No statistical method was used to predetermine sample size. Data are presented as mean ± s.d. as indicated in each figure legend. Comparison between two groups assuming normal distribution was made with twotailed Student's t-test, and Welch's correction was applied when variances were unequal, which was determined by F-test. A value of Po 0.05 was considered significant.
Additional materials and methods are described in Supplementary Materials and Methods, and Supplementary Tables 2-4.
RESULTS
KDM6B confers MM cell growth and survival
We first assessed KDM6B expression in MM patient samples using publicly available data sets. Expression of KDM6B was significantly elevated in MM patient samples compared with healthy donor plasma cells (Figure 1a ), suggesting the role of KDM6B in the pathogenesis of MM. KDM6B protein expression was also verified by immunoblotting in eight MM cell lines and three primary MM samples, while KDM6B protein was not detected in three healthyvolunteer-derived peripheral blood mononuclear cells ( Figure 1b ). We therefore explored the biologic role of KDM6B in MM cells.
We transduced short hairpin (sh) RNA against KDM6B (shKDM6B) or control shRNA against luciferase (shLuc) into MM cell lines. Depletion of KDM6B protein was confirmed in shKDM6B-transduced cells (Figure 2a ). In contrast, transduction of shKDM6B had little effect on closely related KDM6A expression, suggesting specific knockdown of KDM6B by the hairpin (Figure 2a ). Although KDM6B is an H3K27 demethylase, [7] [8] [9] we observed that global H3K27me3 level was minimally affected after KDM6B knockdown (Figure 2a ). Of note, knockdown of KDM6B reduced growth of 6 MM cell lines tested ( Figure 2b ). Cell growth was inhibited even in the presence of MM patient-derived BMSC conditioned medium (BMSC CM) after knockdown of KDM6B ( Supplementary Figure 1) . To confirm the result of shRNA knockdown experiments, we introduced single guide (sg) RNA targeting KDM6B into MM.1S and RPMI 8226 cell lines stably expressing Cas9. The reduction of KDM6B protein level was validated by immunoblot ( Figure 2c To investigate the underlying mechanism of cell growth inhibition in KDM6B-knockdown cells, we quantified apoptotic cells by flow cytometry using Annexin V staining. As shown in Figure 3a , percentages of apoptotic cells were significantly elevated after KDM6B knockdown in MM cell lines. Furthermore, cleaved forms of caspase-3, caspase-7 and poly (ADP-ribose) polymerase (PARP) (markers of the execution apoptosis pathway) were increased after KDM6B knockdown, except for lack of cleavage of caspase-3 in RPMI 8226 cells, suggesting that KDM6B knockdown-induced apoptosis is dependent on caspase-7 in this cell line ( Figure 3b ). We further asked whether the intrinsic or extrinsic pathway is involved in the apoptosis induced by KDM6B knockdown. Immunoblot analyses showed increased cleavage of caspase-8 in KDM6B-knockdown cells with little cleavage of caspase-9, indicating involvement of the extrinsic apoptosis pathway (Figure 3b ). Consistent with this finding, caspase-8 inhibitor Z-IETD-FMK partially blocked KDM6B knockdowninduced cell growth inhibition in MM.1S cells, whereas caspase-9 inhibitor Z-LEHD-FMK did not; rather it enhanced cell death, similar to the previous observation in B-lineage cells ( Supplementary Figure 3 ). 20 We next examined the effect of KDM6B knockdown on cell proliferation. As shown in Figure 3c , BrdU incorporation was significantly decreased after silencing of KDM6B in MM cell lines, while cell cycle profile was minimally altered (Supplementary Figure 4) . Taken together, these results indicate that knockdown of KDM6B induces apoptosis and reduces cell proliferation, thereby impairing MM cell growth.
KDM6B is upregulated by NF-κB pathway in MM NF-κB pathway plays an essential role in the survival of MM. 21, 22 Previous studies have shown that NF-κB regulates KDM6B expression in some cell types. 7, 14 We therefore hypothesized that KDM6B, as a downstream target of NF-κB, may mediate MM cell growth. To that end, we examined whether KDM6B in MM cells is also regulated by NF-κB. Activation of NF-κB pathway by TNF-α, evidenced by increased phospho-IκBα, resulting IκBα protein degradation, as well as increased phospho-p65 (Figure 4a not alter KDM6A expression. We confirmed that KDM6B expression was also induced by additional 4 MM patients' BMSC CMs in MM.1S cells ( Supplementary Figure 5b) . Similar to TNF-α stimulation, BMSC CM-mediated KDM6B induction was significantly decreased in the presence of MLN120B (Figure 4c ), suggesting that KDM6B is induced by BMSCs, at least in part, via NF-κB signaling pathway in MM cells. We next asked whether KDM6B mediates MM cell growth under NF-κB pathway. Endogenous KDM6B expression was significantly reduced after 72 h treatment with MLN120B ( Supplementary  Figure 6a ), associated with growth inhibition in MM.1S cells (Supplementary Figure 6b) . The ectopic expression of KDM6B partially rescued MM.1S cells from this growth inhibition ( Supplementary Figure 6b ), suggesting KDM6B is at least one of the downstream effectors of NF-κB pathway in MM. The limited rescue effect of the ectopic KDM6B expression also implies the existence of other important effectors of NF-κB pathway in MM.
KDM6B regulates expression of MAPK pathway-related genes in MM
To reveal the downstream targets of KDM6B in MM, we next performed differential gene expression analysis using RNA-seq after knockdown of KDM6B in MM.1S cells (Supplementary Table 5 ). Pathway analysis using DAVID Bioinformatics Resources 23, 24 revealed that Toll-like receptor signaling pathway genes were significantly downregulated after KDM6B knockdown (P = 0.01 at KEGG_PATHWAY, P = 0.0079 at BIOCARTA; Figure 5a ), consistent with a previous observation that KDM6B participates in the inflammatory transcriptional response. 25 Interestingly, genes related to MAPK signaling cascade, a major growth and survival pathway in MM, were also significantly downregulated after KDM6B knockdown (P = 0.0029 at KEGG_PATHWAY, P = 0.0013 at BIOCARTA; Figure 5a ). Validation by quantitative real-time PCR showed that knockdown of KDM6B significantly reduced expression of MAPK pathway-related genes such as RASGRP3, PRKCB, ELK1 and FOS in 6 MM cell lines (Figure 5b ; Supplementary Figure 7a ). We also observed reduced protein expression of ELK1 and FOS after KDM6B knockdown in these MM cell lines ( Supplementary Figure 7b ). CRISPR-mediated KDM6B knockout also demonstrated that depletion of KDM6B decreased expression of RASGRP3, PRKCB, ELK1 and FOS (Figure 5c ). Conversely, overexpression of KDM6B increased expression of 3 of these MAPK pathway-related genes, but not ELK1 expression, suggesting that constitutive ELK1 expression is maintained at the maximum level by endogenous level of KDM6B ( Supplementary Figure 8) . We next tested whether KDM6B is directly recruited to the loci of MAPK pathway-related genes. Since chromatin immunoprecipitation (ChIP)-grade KDM6B antibody is unavailable, we generated HA-tagged KDM6B (HA-KDM6B) stably expressing MM.1S cells for ChIP assays (Figure 6a ). Fragments of cross-linked chromatin were immunoprecipitated with anti-HA antibody, followed by quantitative PCR. Empty vector-transduced cells were used as a negative control. As shown in Figure 6b , ChIP signals were enriched at the transcriptional start sites of RASGRP3, PRKCB, ELK1 and FOS genes in HA-KDM6B expressing cells, but not in empty vector-transduced cells, indicating that KDM6B binds to the transcriptional start sites of these genes. We next evaluated H3K27me3 level at these regions after knockdown of KDM6B, since KDM6B is an H3K27 demethylase. Unexpectedly, H3K27me3 level was not increased at these sites in KDM6B-knockdown MM.1S cells compared with control cells (Figure 6c ). Previous studies have reported the KDM6B functions that are independent of demethylase activity; [25] [26] [27] hence, we hypothesized that KDM6B may regulate MAPK pathway genes via an enzymatically independent function in MM cells. To test this possibility, we expressed demethylase-dead KDM6B (H1390A) cDNA in MM.1S cells. Expression of mutant KDM6B enhanced growth of MM.1S cells (Figure 7a) , and induced expression of RASGRP3, PRKCB and FOS (Figure 7b ), similar to wild-type KDM6B, indicating that KDM6B promotes MM cell growth and regulates MAPK pathway genes independent of its catalytic function. Consistent with these findings, GSK-J4, H3K27 demethylases inhibitor which blocks KDM6B enzymatic activity but induces KDM6B expression ( Supplementary Figure 9 ), upregulates expression of these MAPK pathway molecules ( Supplementary Figure 9 ). Taken together, these results indicate that KDM6B regulates MAPK pathway molecules in a demethylase-independent manner in MM cells. lines, and immunoblot analyses confirmed reduction of ELK1 or FOS protein after transduction of each shRNA (Figure 8a ). Under these condition, cell growth was markedly reduced in MM cell lines (Figure 8b) , indicating that these transcription factors mediate MM cell growth.
Finally, we determined whether BMSCs induce FOS expression, as BMSCs activate NF-κB pathway and induce KDM6B expression in MM cells. As shown in Figure 8c , BMSC CM induced FOS expression in MM.1S cells. This induction was abrogated by KDM6B knockdown (Figure 8c ), suggesting that BMSC-induced FOS expression is mediated by KDM6B in MM cells.
DISCUSSION
In this study, we show that KDM6B is induced by activation of NF-κB pathway, and that KDM6B in turn upregulates molecules of MAPK pathway, thereby promoting MM cell growth and survival. Previous reports have shown KDM6B dependence in other types of cancers, [14] [15] [16] [17] but those mechanisms are distinct from our findings in MM. In T-cell acute lymphoblastic leukemia, KDM6B regulates genes related to NOTCH pathway, 14 whereas silencing of KDM6B has no effect on NOTCH pathway-related genes in MM cells ( Supplementary Table 5 ). Interestingly, Zhang et al. 17 showed subtype-specific KDM6B dependence in diffuse large B-cell lymphoma (DLBCL): KDM6B maintains survival of germinal center B-cell-like DLBCL through activating BCL2 expression, whereas it promotes activated B-cell-like DLBCL survival via upregulating IRF4 expression. IRF4 is also known to be an essential survival factor in MM, 28, 29 but IRF4 expression is not affected by knockdown of KDM6B in MM cells. A tumor suppressor role of KDM6B has also been reported. 10, 11 Oncogenic stress-induced KDM6B upregulates INK4A/ARF, resulting in cellular senescence, but not in MM. These data suggest the cancer-type-specific roles of KDM6B. We here demonstrate that KDM6B regulates MAPK pathwayrelated genes in a catalytically independent manner. Several studies have highlighted the demethylase activity-independent functions of KDM6B in different contexts. [25] [26] [27] Using ChIPsequencing, De Santa et al. 25 showed that KDM6B is preferentially recruited to transcriptional start sites where H3K27 is not methylated in LPS-activated macrophages, suggesting that KDM6B regulates transcription of target genes independently of H3K27 demethylation. KDM6B has also been shown to be required for chromatin remodeling in a demethylase-independent manner by mediating T-bet interaction with a Brg1-containing SWI/SNF complex in Th1 cells. 26 Furthermore, KDM6B facilitates ubiquitination of PHF20 by E3 ubiquitin ligase Trim26, thereby triggering PHF20 degradation. 27 These studies support the notion that KDM6B mediates various biological functions not only via its H3K27 demethylase activity, but also its non-enzymatic activity.
Our current data suggest that KDM6B represents a potential therapeutic target in MM, and that targeting KDM6B protein itself, but not enzymatic activity, is necessary, given its demethylaseindependent function in MM. Inhibition of NF-κB pathway may be one of the promising strategies, since KDM6B expression is, at least in part, regulated by NF-κB. For direct targeting of KDM6B, proteolysis targeting chimeras (PROTACs) technology might be suitable. PROTACs are chimera drugs that recruit specific target protein to E3 ubiquitin ligase, thereby facilitating ubiquitination and resulting degradation of target protein. 30 Recent reports in this field have shown that target-specific degradation can be achieved at nano molar range within 4 h using two different ubiquitin ligase ligands in cultured cells. [31] [32] [33] [34] Furthermore, two of these reports have demonstrated that their PROTACs reduce the target protein levels even in xenografted tumor cells. 32, 34 Thus, PROTACs might be a promising technology for targeting KDM6B protein, even though there is a requirement to identify a KDM6Bspecific small-molecule ligand for the application of PROTACs.
In conclusion, we identify KDM6B as a key molecule promoting growth and survival of MM cells, independent of its demethylase activity. Our work delineates the role of KDM6B in MM pathogenesis, and validates KDM6B as a promising therapeutic target in MM.
